<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">660</journal-id><journal-id journal-id-type="pmc-domain">jco</journal-id><journal-id journal-id-type="publisher-id">JCO</journal-id><journal-title-group><journal-title>Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0732-183X</issn><issn pub-type="epub">1527-7755</issn><publisher><publisher-name>American Society of Clinical Oncology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6804844</article-id><article-id pub-id-type="pmcid-ver">PMC6804844.1</article-id><article-id pub-id-type="pmcaid">6804844</article-id><article-id pub-id-type="pmcaiid">6804844</article-id><article-id pub-id-type="pmid">31188727</article-id><article-id pub-id-type="doi">10.1200/JCO.18.02439</article-id><article-id pub-id-type="publisher-id">1802439</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="subjects"><compound-subject><compound-subject-part content-type="code">HEMA</compound-subject-part><compound-subject-part content-type="label">HEMATOLOGIC MALIGNANCIES: LEUKEMIAS</compound-subject-part></compound-subject><compound-subject><compound-subject-part content-type="code">HEMA</compound-subject-part><compound-subject-part content-type="label">HEMATOLOGIC MALIGNANCIES: LYMPHOMAS</compound-subject-part></compound-subject><compound-subject><compound-subject-part content-type="code">PEDI</compound-subject-part><compound-subject-part content-type="label">PEDIATRIC ONCOLOGY: PEDIATRIC CANCERS</compound-subject-part></compound-subject><compound-subject><compound-subject-part content-type="code">FAZE</compound-subject-part><compound-subject-part content-type="label">PHASE I AND CLINICAL PHARMACOLOGY</compound-subject-part></compound-subject><compound-subject><compound-subject-part content-type="code">CMPL</compound-subject-part><compound-subject-part content-type="label">TREATMENT-RELATED COMPLICATIONS</compound-subject-part></compound-subject></subj-group><subj-group subj-group-type="heading"><subject>ORIGINAL REPORTS</subject><subj-group><subject>Leukemia and Bone Marrow Transplantation</subject></subj-group></subj-group></article-categories><title-group><article-title>Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge</article-title><alt-title alt-title-type="short">Antibodies and Allergies to PEG-Asparaginase</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yiwei</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smith</surname><given-names initials="CA">Colton A.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Panetta</surname><given-names initials="JC">John C.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="W">Wenjian</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thompson</surname><given-names initials="LE">Lauren E.</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Counts</surname><given-names initials="JP">Jacob P.</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Molinelli</surname><given-names initials="AR">Alejandro R.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pei</surname><given-names initials="D">Deqing</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kornegay</surname><given-names initials="NM">Nancy M.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Crews</surname><given-names initials="KR">Kristine R.</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Swanson</surname><given-names initials="H">Hope</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cheng</surname><given-names initials="C">Cheng</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karol</surname><given-names initials="SE">Seth E.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Evans</surname><given-names initials="WE">William E.</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Inaba</surname><given-names initials="H">Hiroto</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pui</surname><given-names initials="CH">Ching-Hon</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jeha</surname><given-names initials="S">Sima</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Relling</surname><given-names initials="MV">Mary V.</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"/></contrib><aff id="aff1"><label><sup>1</sup></label>St Jude Children&#8217;s Research Hospital, Memphis, TN</aff><aff id="aff2"><label><sup>2</sup></label>University of Colorado Anschutz Medical Campus, Aurora, CO</aff><aff id="aff3"><label><sup>3</sup></label>University of Tennessee Health Science Center, Memphis, TN</aff></contrib-group><author-notes><corresp id="cor1">Mary V. Relling, PharmD, Department of Pharmaceutical Sciences, St Jude Children&#8217;s Research Hospital, 262 Danny Thomas Pl, MS 313, Memphis, TN 38105; e-mail: <email>mary.relling@stjude.org</email>.</corresp></author-notes><pub-date pub-type="ppub"><day>10</day><month>8</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>12</day><month>6</month><year>2019</year></pub-date><volume>37</volume><issue>23</issue><issue-id pub-id-type="pmc-issue-id">340175</issue-id><fpage>2051</fpage><lpage>2061</lpage><history><date date-type="accepted"><day>8</day><month>5</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>10</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>30</day><month>10</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-10-13 21:25:19.427"><day>13</day><month>10</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2019 by American Society of Clinical Oncology</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>American Society of Clinical Oncology</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JCO.18.02439.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:title="pdf" xlink:href="JCO.18.02439.pdf"/><abstract><sec><title>PURPOSE</title><p>Pegaspargase (PEG-ASP) has largely replaced native <italic toggle="yes">Escherichia</italic>
<italic toggle="yes">coli</italic> asparaginase (L-ASP) in the treatment of acute lymphoblastic leukemia because of its longer half-life and lower immunogenicity. Risk factors for allergic reactions to PEG-ASP remain unclear. Here, we identify risk factors for reactions in a front-line acute lymphoblastic leukemia trial and assess the usefulness of serum antibodies for diagnosing allergy and predicting rechallenge outcome.</p></sec><sec><title>PATIENTS AND METHODS</title><p>PEG-ASP was administered to 598 patients in St Jude&#8217;s Total XVI study. Results were compared with Total XV study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifiers: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00549848">NCT00549848</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00137111">NCT00137111</ext-link>), which used native L-ASP. Serum samples (n = 5,369) were analyzed for anti&#8211;PEG-ASP immunoglobulin G by enzyme-linked immunosorbent assay. Positive samples were tested for anti&#8211;polyethylene glycol (PEG) and anti&#8211;L-ASP. We analyzed potential risk factors for reactions and associations between antibodies and reactions, rechallenge outcomes, and PEG-ASP pharmacokinetics.</p></sec><sec><title>RESULTS</title><p>Grade 2 to 4 reactions were less common in the Total XVI study with PEG-ASP (81 [13.5%] of 598) than in the Total XV study with L-ASP (169 [41.2%] of 410; <italic toggle="yes">P</italic> = 1.4 &#215; 10<sup>&#8722;23</sup>). For Total XVI, anti-PEG, not anti&#8211;L-ASP, was the predominant component of anti&#8211;PEG-ASP antibodies (96%). In a multivariable analysis, more intrathecal therapy (IT) predicted fewer reactions (<italic toggle="yes">P</italic> = 2.4 &#215; 10<sup>&#8722;5</sup>), which is consistent with an immunosuppressant contribution of IT. Anti&#8211;PEG-ASP was associated with accelerated drug clearance (<italic toggle="yes">P</italic> = 5.0 &#215; 10<sup>&#8722;6</sup>). Failure of rechallenge after initial reactions was associated with anti&#8211;PEG-ASP (<italic toggle="yes">P</italic> = .0078) and was predicted by the occurrence of angioedema with first reaction (<italic toggle="yes">P</italic> = .01).</p></sec><sec><title>CONCLUSION</title><p>Less IT therapy was the only independent clinical risk factor for reactions to PEG-ASP. PEG, and not L-ASP, is the major antigen that causes allergic reactions. Anti&#8211;PEG-ASP has utility in predicting and confirming clinical reactions to PEG-ASP as well as in identifying patients who are most likely to experience failure with rechallenge.</p></sec></abstract><kwd-group kwd-group-type="subject_thes"><compound-kwd><compound-kwd-part content-type="term">3282-3306-3348-9719</compound-kwd-part><compound-kwd-part content-type="thesTerm">Asparaginase</compound-kwd-part><compound-kwd-part content-type="hits">30</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">261-492-199-2823-7675</compound-kwd-part><compound-kwd-part content-type="thesTerm">Allergic reactions</compound-kwd-part><compound-kwd-part content-type="hits">11</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">613-615-646-2680</compound-kwd-part><compound-kwd-part content-type="thesTerm">Antibodies</compound-kwd-part><compound-kwd-part content-type="hits">11</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">298-145-222</compound-kwd-part><compound-kwd-part content-type="thesTerm">Clinical trials</compound-kwd-part><compound-kwd-part content-type="hits">9</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">613-3262-447</compound-kwd-part><compound-kwd-part content-type="thesTerm">Risk factors</compound-kwd-part><compound-kwd-part content-type="hits">8</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">613-225-2575-2427</compound-kwd-part><compound-kwd-part content-type="thesTerm">Intrathecal administration</compound-kwd-part><compound-kwd-part content-type="hits">7</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">613-213-3369-9142-3598</compound-kwd-part><compound-kwd-part content-type="thesTerm">Enzyme linked immunosorbent assay</compound-kwd-part><compound-kwd-part content-type="hits">6</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">613-3262-447</compound-kwd-part><compound-kwd-part content-type="thesTerm">Risk factors</compound-kwd-part><compound-kwd-part content-type="hits">4</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">613-615-646-2680</compound-kwd-part><compound-kwd-part content-type="thesTerm">Antibodies</compound-kwd-part><compound-kwd-part content-type="hits">3</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">613-225-2575-2427</compound-kwd-part><compound-kwd-part content-type="thesTerm">Intrathecal administration</compound-kwd-part><compound-kwd-part content-type="hits">3</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">283-224-171-3390</compound-kwd-part><compound-kwd-part content-type="thesTerm">Acute lymphoblastic leukemia</compound-kwd-part><compound-kwd-part content-type="hits">2</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">261-492-199-2823-7675</compound-kwd-part><compound-kwd-part content-type="thesTerm">Allergic reactions</compound-kwd-part><compound-kwd-part content-type="hits">2</compound-kwd-part></compound-kwd></kwd-group><kwd-group kwd-group-type="drug_thes"><compound-kwd><compound-kwd-part content-type="term">281</compound-kwd-part><compound-kwd-part content-type="thesTerm">pegaspargase</compound-kwd-part><compound-kwd-part content-type="hits">75</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">187</compound-kwd-part><compound-kwd-part content-type="thesTerm">asparaginase</compound-kwd-part><compound-kwd-part content-type="hits">35</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">281</compound-kwd-part><compound-kwd-part content-type="thesTerm">pegaspargase</compound-kwd-part><compound-kwd-part content-type="hits">8</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">281</compound-kwd-part><compound-kwd-part content-type="thesTerm">pegaspargase</compound-kwd-part><compound-kwd-part content-type="hits">2</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">112</compound-kwd-part><compound-kwd-part content-type="thesTerm">methotrexate</compound-kwd-part><compound-kwd-part content-type="hits">2</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">187</compound-kwd-part><compound-kwd-part content-type="thesTerm">asparaginase</compound-kwd-part><compound-kwd-part content-type="hits">1</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">2840</compound-kwd-part><compound-kwd-part content-type="thesTerm">diphenhydramine</compound-kwd-part><compound-kwd-part content-type="hits">1</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">53</compound-kwd-part><compound-kwd-part content-type="thesTerm">dexamethasone</compound-kwd-part><compound-kwd-part content-type="hits">1</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="term">2016</compound-kwd-part><compound-kwd-part content-type="thesTerm">prednisolone</compound-kwd-part><compound-kwd-part content-type="hits">1</compound-kwd-part></compound-kwd></kwd-group><counts><fig-count count="5"/><table-count count="1"/><equation-count count="0"/><ref-count count="44"/><page-count count="12"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name> SJS Export </meta-name><meta-value>v1</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>